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ABSTRACT
Paraproteinemia is precipitated by an accumulation of monoclonal plasma cells or B lymphocytes. Idiopathic 
neuropathies that are associated with paraproteinemia account for only 10% of the neuropathies. Paraprotein acts like 
an antibody and  is targeted against myelin and axons present in the peripheral nerves. Despite being of interest for 
quite a long time, the caudal relationship between paraproteinemias and peripheral neuropathies still remains a 
sorcery. We report a case of a middle aged male who presented with pain and parasthesias in both arms and legs. His 
workup revealed him to be having a paraproteinemic neuropathy consistent with IgA Lambda chains that account for 
being the most rare type of monoclonal gammopathy than IgM or IgG having the potential to progress to smouldering 
multiple myeloma.
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C A S E  R E P O R T
INTRODUCTION: Paraproteinemic neuropathies are a 
heterogeneous group of neuropathies, which share the 
common feature of a homogeneous immunoglobulin in 
the serum. Approximately 10% of all idiopathic 
neuropathies are associated with paraproteinemia.[1] 
Monoclonal gammopathy of undetermined significance 
(MGUS) occurs in over 5.3% of the general population 
over the age of 70 and the incidence increases with 
age being more common in men.[2] The type of M 
protein in monoclonal gammopathy associated with 
peripheral neuropathy is most commonly IgM while IgG 
and IgA neuropathies are less common.[3] In one study, 
approximately 60% of neuropathies associated with 
monoclonal gammopathy were IgM, 30% were IgG, and 
10% were IgA. [4] IgA  protein appears to be associated 
with a lesser predilection for causing peripheral 
neuropathy compared to IgM or IgG MGUS 
combined.[5] In a study of 74 patients with MGUS, 8 of 
26 IgM MGUS patients (31%) had neuropathy, 
compared to 2 of 34 IgG MGUS patients (6%) and 2 of 
14 IgA MGUS patients (14%).[5] Paraproteinemic 
neuropathy IgA affects some or all sensory 
modalitieswhich cause allodynia, hyperpathia, cramps 
with distal weakness. These neuropathies are typically 
manifested neurologically as a demyelinating type of 
sensori-motor polyneuropathy. Sometimes, multi-organ 
involvement is also seen. Patients with paraproteinemic 
neuropathy have an increased risk of axial bone 
fractures, thrombo embolism, peripheral neuropathy 
and secondary malignancies.[6] Therapies for IgA 
paraproteinemic neuropathy depend on the particular 
subtype,the patho-physiology involved, ranging from 
intravenous immunoglobulins (IVIGs), plasma exchange 
sessions, corticosteroids, rituximab and various 
chemotherapies. In terms of response to therapy there 
is no distinction seen between demyelinating and 
axonal patterns of neuropathy,Possible malignant 
conversion of underlying benign monoclonal 
gammopathy has to be closely monitored with risk 
factors for malignant transformation including 
progressive worsening of neuropathy and rising titers of 
monoclonal protein.[7] 
Case Report:
A 52 years of age Pakistani male presented to 
neurology clinic with a 12 months history of numbness, 
tingling, pain in both lower extremities and symptoms 
progressed to involve both his arms for 6 months. Three 
months prior to presentation he started developing 
slowly progressive asymmetrical weakness of both legs, 
without any sphincteric involvement. There was no 
history of fever, cough, diarrhea or constipation. There 
was no past history of joint pains, weight loss, 
photosensitivity, polyuria or polydipsia. He belongs to a 
poor socioeconomic group and is a gardener by 
occupation with 3 children. He is a nonsmoker and 
denies alcoholism. There is history of essential 
hypertension for 3 years and he is on tablet atenolol 
50mg daily. Rest of the drug and family history were nil 
of note. On physical examination, a middle-aged 
gentleman alert and oriented to time, place and 
person. The patient's oral temperature was 98.6°F with 
a regular pulse of 68 beats/minute. His blood pressure 
was 130/80 mm Hg with no postural drop and 
respiratory rate was 14/ minute. He had distal wasting 
of lower extremities with bilateral footdrop (Figure, A). 
Muscle tone was decreased in all four limbs with 
areflexia and bilaterally mute plantar response. He had 
a  Medical Research Council (MRC) sum score of 
30/60.  Pin prick sensation was lost in a glove and 
stocking distribution with normal perianal sensation. He 
had a high steppage gait. Signs of meningeal irritation 
were absent. Abdominal examination was did not reveal 
any palpable mass, organomegaly or ascites. The 
patient's precordial examination revealed normal heart 
sounds and chest examination revealed normal 
vesicular breathing. The laboratory analysis 
demonstrated a normal blood complete picutre and 
erythrocyte sedimentation rate. Liver and renal function 
tests, serum glucose levels, muscle enzymes, ECG and 
chest X-ray were unremarkable. His nerve conduction 
studies and electromyography were consistent with a 
chronic sensori-motor demyelinating type of 
polyneuropathy with secondary axonal damage (Figure, 
B). Lumbar puncture for CSF analysis showed elevated 
CSF protein of 0.92g/l. His HbA1c, thyroid function 
tests, and serum B12 levels were normal. His ANA, RA 
factor, HIV serology, HbsAg, and anti-HCV were 
negative. CT scan of the chest, abdomen, and pelvis 
were unremarkable. Serum protein electrophoresis 
revealed a discrete spike in the monoclonal paraprotein 
consisting of IgA Lambda with serum IgA levels 
markedly raised to 13 mg/dl (Normal range 1-7 mg/dL) 
(Figure, C) Urine for Bence Jones proteins didn’t show 
light chains. Bone scan, skeletal survey and bone 
marrow biopsy were negative.Our patient fulfilled the 
criteria for MGUS established by the International 
Myeloma Working Group and the World Health 
organization consistent with IgA lambda monoclonal 
gammopathy, Therefore, the final diagnosis of IgA 
paraproteinemic neuropathy associated with MGUS 
was made. The patient was given a trial of 5 sessions of 
plasmapheresis. Mild improvement in motor and 
sensory symptoms was observed, however, his bilateral 
foot drop persisted. He was given an 
ankle-foot-orthosis (AFO) for his foot drop. He is 
undergoing physiotherapy and has been advised regular 
follow ups in Neurology and Oncology clinics to plan for 
immunomodulatory treatment.
 
Figure A: BILATERAL FOOT DROP
Figure B: Figure B: Nerve Conduction studies showing a 
demyelinating pattern with a motor amplitude drop, 
prolong latencies and an abnormal temporal dispersion
Figure C: Serum protein electrophoresis showing an IgA 
spike (arrow head)
DISCUSSION:
Patients with paraproteinemic disorders exhibit distinct 
neuropathic phenotypes, often with characteristic 
identifiable clinical features. Frequently prognosis is not 
well-defined and in many cases is still unknown. 
Neuropathies can lead to disability, loss of 
independence and social isolation especially in the 
elderly. They warrant adequate work up for diagnosis 
which may sometimes be very extensive. Neuropathies 
associated with paraproteinemia have heterogeneous 
clinical, neurophysiological, neuropathological and 
hematological features. These necessitate prompt and 
appropriate work up and management to avoid 
permanent disability. There is no known role until now 
for chemotherapy and no treatment is recommended 
and required for patients with MGUS.[8] These patients 
must be followed over time with history and clinical 
assessment for disease progression. All patients should 
undergo laboratory evaluation for disease progression 
six months after diagnosis with serum and urinary 
M-protein, complete blood count, creatinine, and 
serum calcium. Periodic laboratory testing should then 
be done in follow-up of high-risk patients using a risk 
stratification system as not all persons with MGUS have 
the same risk of disease progression. Therefore, the 
management of a patient with MGUS requires an 
understanding of the risk of progression to symptomatic 
disease requiring therapy. MGUS neuropathy is closely 
linked to chronic inflammatory demyelinating 
polyneuropathy.[9] However, this association still 
remains unclear. The paramount feature of CIDP i.e 
conduction blocks sometimes occur in MGUS as well. 
The cerebrospinal fluid (CSF) proteins are usually 
elevated in both these conditions and their response to 
immune-modulating treatments is substantial.[10] 
The EFNS guidelines on the treatment options of 
chronic inflammatory demyelinating 
polyradiculoneuropathies also suggests screening for 
paraproteins in all the patients diagnosed as CIDP and 
if the screening comes out to be positive then it must 
be labeled as paraproteinemia.[11] The appropriate 
therapy for paraproteinemic neuropathies has yet to be 
established. Patients with  IgA MGUS improve 
symptomatically within days or weeks after high-dose 
intravenous immunoglobulins (0.4 g/kg of body weight) 
daily for 5 days, a total of 4 to 5 plasma exchange 
sessions (a total of 220 ml/kg) or therapy with 
corticosteroids often in combination with 
immune-suppressants. Class I evidence documents 
plasma exchange to be effective in peripheral 
neuropathies associated with MGUS of the IgG and IgA, 
but not IgM, types.[12] Another treatment is 
immunoadsorption, which is a blood purification 
technique used to eliminate pathogenic antibodies but 
its role has not been fully proven through trials. 
Interferon alpha was also found to beneficial in one 
trial.[13] These treatment regimens produce only a 
transitory improvement and require recapitulation for 
several months depending upon the patient’s 
response. If one treatment modality is unsuccessful, 
one may initiate an alternative modality which may lead 
to alleviation of symptoms. More studies are required 
to have a better understanding of the patho-physiology 
of various mechanisms involved and better biomarkers 
to ascertain the usefulness and efficacy of therapy.
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polyradiculoneuropathies also suggests screening for 
paraproteins in all the patients diagnosed as CIDP and 
if the screening comes out to be positive then it must 
be labeled as paraproteinemia.[11] The appropriate 
therapy for paraproteinemic neuropathies has yet to be 
established. Patients with  IgA MGUS improve 
symptomatically within days or weeks after high-dose 
intravenous immunoglobulins (0.4 g/kg of body weight) 
daily for 5 days, a total of 4 to 5 plasma exchange 
sessions (a total of 220 ml/kg) or therapy with 
corticosteroids often in combination with 
immune-suppressants. Class I evidence documents 
plasma exchange to be effective in peripheral 
neuropathies associated with MGUS of the IgG and IgA, 
but not IgM, types.[12] Another treatment is 
immunoadsorption, which is a blood purification 
technique used to eliminate pathogenic antibodies but 
its role has not been fully proven through trials. 
Interferon alpha was also found to beneficial in one 
trial.[13] These treatment regimens produce only a 
transitory improvement and require recapitulation for 
several months depending upon the patient’s 
response. If one treatment modality is unsuccessful, 
one may initiate an alternative modality which may lead 
to alleviation of symptoms. More studies are required 
to have a better understanding of the patho-physiology 
of various mechanisms involved and better biomarkers 
to ascertain the usefulness and efficacy of therapy.
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Case Report:
A 52 years of age Pakistani male presented to 
neurology clinic with a 12 months history of numbness, 
tingling, pain in both lower extremities and symptoms 
progressed to involve both his arms for 6 months. Three 
months prior to presentation he started developing 
slowly progressive asymmetrical weakness of both legs, 
without any sphincteric involvement. There was no 
history of fever, cough, diarrhea or constipation. There 
was no past history of joint pains, weight loss, 
photosensitivity, polyuria or polydipsia. He belongs to a 
poor socioeconomic group and is a gardener by 
occupation with 3 children. He is a nonsmoker and 
denies alcoholism. There is history of essential 
hypertension for 3 years and he is on tablet atenolol 
50mg daily. Rest of the drug and family history were nil 
of note. On physical examination, a middle-aged 
gentleman alert and oriented to time, place and 
person. The patient's oral temperature was 98.6°F with 
a regular pulse of 68 beats/minute. His blood pressure 
was 130/80 mm Hg with no postural drop and 
respiratory rate was 14/ minute. He had distal wasting 
of lower extremities with bilateral footdrop (Figure, A). 
Muscle tone was decreased in all four limbs with 
areflexia and bilaterally mute plantar response. He had 
a  Medical Research Council (MRC) sum score of 
30/60.  Pin prick sensation was lost in a glove and 
stocking distribution with normal perianal sensation. He 
had a high steppage gait. Signs of meningeal irritation 
were absent. Abdominal examination was did not reveal 
any palpable mass, organomegaly or ascites. The 
patient's precordial examination revealed normal heart 
sounds and chest examination revealed normal 
vesicular breathing. The laboratory analysis 
demonstrated a normal blood complete picutre and 
erythrocyte sedimentation rate. Liver and renal function 
tests, serum glucose levels, muscle enzymes, ECG and 
chest X-ray were unremarkable. His nerve conduction 
studies and electromyography were consistent with a 
chronic sensori-motor demyelinating type of 
polyneuropathy with secondary axonal damage (Figure, 
B). Lumbar puncture for CSF analysis showed elevated 
CSF protein of 0.92g/l. His HbA1c, thyroid function 
tests, and serum B12 levels were normal. His ANA, RA 
factor, HIV serology, HbsAg, and anti-HCV were 
negative. CT scan of the chest, abdomen, and pelvis 
were unremarkable. Serum protein electrophoresis 
revealed a discrete spike in the monoclonal paraprotein 
consisting of IgA Lambda with serum IgA levels 
markedly raised to 13 mg/dl (Normal range 1-7 mg/dL) 
(Figure, C) Urine for Bence Jones proteins didn’t show 
light chains. Bone scan, skeletal survey and bone 
marrow biopsy were negative.Our patient fulfilled the 
criteria for MGUS established by the International 
Myeloma Working Group and the World Health 
organization consistent with IgA lambda monoclonal 
gammopathy, Therefore, the final diagnosis of IgA 
paraproteinemic neuropathy associated with MGUS 
was made. The patient was given a trial of 5 sessions of 
plasmapheresis. Mild improvement in motor and 
sensory symptoms was observed, however, his bilateral 
foot drop persisted. He was given an 
ankle-foot-orthosis (AFO) for his foot drop. He is 
undergoing physiotherapy and has been advised regular 
follow ups in Neurology and Oncology clinics to plan for 
immunomodulatory treatment.
 
Figure A: BILATERAL FOOT DROP
Figure B: Figure B: Nerve Conduction studies showing a 
demyelinating pattern with a motor amplitude drop, 
prolong latencies and an abnormal temporal dispersion
Figure C: Serum protein electrophoresis showing an IgA 
spike (arrow head)
DISCUSSION:
Patients with paraproteinemic disorders exhibit distinct 
neuropathic phenotypes, often with characteristic 
identifiable clinical features. Frequently prognosis is not 
well-defined and in many cases is still unknown. 
Neuropathies can lead to disability, loss of 
independence and social isolation especially in the 
elderly. They warrant adequate work up for diagnosis 
which may sometimes be very extensive. Neuropathies 
associated with paraproteinemia have heterogeneous 
clinical, neurophysiological, neuropathological and 
hematological features. These necessitate prompt and 
appropriate work up and management to avoid 
permanent disability. There is no known role until now 
for chemotherapy and no treatment is recommended 
and required for patients with MGUS.[8] These patients 
must be followed over time with history and clinical 
assessment for disease progression. All patients should 
undergo laboratory evaluation for disease progression 
six months after diagnosis with serum and urinary 
M-protein, complete blood count, creatinine, and 
serum calcium. Periodic laboratory testing should then 
be done in follow-up of high-risk patients using a risk 
stratification system as not all persons with MGUS have 
the same risk of disease progression. Therefore, the 
management of a patient with MGUS requires an 
understanding of the risk of progression to symptomatic 
disease requiring therapy. MGUS neuropathy is closely 
linked to chronic inflammatory demyelinating 
polyneuropathy.[9] However, this association still 
remains unclear. The paramount feature of CIDP i.e 
conduction blocks sometimes occur in MGUS as well. 
The cerebrospinal fluid (CSF) proteins are usually 
elevated in both these conditions and their response to 
immune-modulating treatments is substantial.[10] 
The EFNS guidelines on the treatment options of 
chronic inflammatory demyelinating 
polyradiculoneuropathies also suggests screening for 
paraproteins in all the patients diagnosed as CIDP and 
if the screening comes out to be positive then it must 
be labeled as paraproteinemia.[11] The appropriate 
therapy for paraproteinemic neuropathies has yet to be 
established. Patients with  IgA MGUS improve 
symptomatically within days or weeks after high-dose 
intravenous immunoglobulins (0.4 g/kg of body weight) 
daily for 5 days, a total of 4 to 5 plasma exchange 
sessions (a total of 220 ml/kg) or therapy with 
corticosteroids often in combination with 
immune-suppressants. Class I evidence documents 
plasma exchange to be effective in peripheral 
neuropathies associated with MGUS of the IgG and IgA, 
but not IgM, types.[12] Another treatment is 
immunoadsorption, which is a blood purification 
technique used to eliminate pathogenic antibodies but 
its role has not been fully proven through trials. 
Interferon alpha was also found to beneficial in one 
trial.[13] These treatment regimens produce only a 
transitory improvement and require recapitulation for 
several months depending upon the patient’s 
response. If one treatment modality is unsuccessful, 
one may initiate an alternative modality which may lead 
to alleviation of symptoms. More studies are required 
to have a better understanding of the patho-physiology 
of various mechanisms involved and better biomarkers 
to ascertain the usefulness and efficacy of therapy.
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